Pharmaceutical industry – Page 35
-
BusinessFDA moves to withdraw swine drug carbadox
Carcinogenic antibiotic has been banned in EU, Canada and Australia for years
-
BusinessUS treasury rules scupper Pfizer–Allergan merger
Government aims to crack down on corporate tax avoidance through ‘inversion’ deals
-
OpinionThrowing things over the fence
Saying ‘That’s someone else’s problem’ is asking for trouble, says Derek Lowe
-
BusinessIndian whistleblower pushes for regulatory reform
Although denied a hearing by India’s supreme court, Dinesh Thakur wants to shake up pharmaceutical safety laws
-
BusinessRoche sketches out Blueprint collaboration
Drug discovery startup will contribute to cancer immunotherapy projects aimed at kinase enzymes
-
BusinessIndia bans 344 combination drugs
Manufacturers appeal to courts to allow continued sales of products the government deems risky
-
OpinionDrugs don’t grow on trees
The trope of companies profiteering from academic discoveries doesn’t bear much scrutiny, says Derek Lowe
-
BusinessSanofi and Merck & Co end vaccines partnership
Two-decade-long alliance will split by end of 2016
-
OpinionForged in righteous flames
Could the debate over pharma price-gouging have positive results for both patients and companies?
-
Business
Pfizer agrees potential $785m fraud settlement
Whistleblower case relates to claims of Wyeth overcharging for acid reflux drugs between 2001 and 2006
-
Business
Lilly loses UK patent challenge
Allergan’s cancer drug generics do not infringe patents, say UK courts
-
Business
GSK fined for stalling antidepressant generics
UK Competition and Markets Authority deems pay-for-delay deal illegal and imposes £45m in fines
-
BusinessMylan to buy Meda in further generics consolidation
£6.9bn deal will give combined company ‘critical mass’ in US market
-
BusinessMedical devices consolidation continues
Abbott to buy Alere for $5.8bn to augment its point-of-care diagnostics business
-
Business
Merck & Co joins hepatitis C party
New drug adds new treatment options and increases competition in premium market
-
BusinessJ&J to cut 3000 jobs in medical devices unit
Cost-saving cuts will help ‘accelerate the pace of innovation’, company claims
-
OpinionThe kids aren’t alright
Making it more attractive for companies to develop paediatric drugs has the potential to improve everyone’s lives
-
BusinessGSK scientists indicted for trade secret theft
Two researchers accused of passing research data and manufacturing details to Chinese firm
-
BusinessClinical trial death highlights hazards
Pain drug trial has left one dead and five hospitalised in France, with little indication as to the cause of the problems
-
BusinessShire bets big on rare diseases
$32bn Baxalta buyout will deepen Shire’s commitment to developing specialist drugs for small patient populations